Tele: 561.316.3330
Breaking Medical Device News

Wednesday, September 22, 2021

HomeSolasia Pharma K.K.Solasia Files New Medical Device Application for episil® in South Korea

Solasia Files New Medical Device Application for episil® in South Korea

Today President & CEO of Solasia, Yoshihiro Arai, announced that the Company has filed a New Medical Device Application for episil® oral liquid (SP-03, hereinafter “episil®”) to the Regulatory Authority in South Korea. Solasia is a specialty pharmaceutical company based in Tokyo, Japan.

episil® has a mechanical action indicated for the management of pain and relief of pain in the oral cavity, and is the only ready-to-use, pocket-sized medical device for such indication. As there are currently no standard treatment for oral mucositis which may be caused by chemotherapy and/or radiotherapy, episil® is expected to provide a new pain relief treatment option for patients with oral mucositis in South Korea.

In 2015, Solasia obtained an exclusive license to develop and commercialize episil® in Japan and China from Camurus AB (STO:CAMX). In 2018, Solasia obtained the right for South Korea. In July 2017, episil® was approved in Japan by the Ministry of Health, Labour and Welfare, with the indication for the management of pain and relief of pain, soothing oral lesions including oral mucositis caused by chemotherapy and/or radiotherapy. Following approval, episil® was launched in Japan in May 2018. In China, episil® has been approved by the National Medical Products Administration (NMPA, formerly CFDA) in February 2019.

Yoshihiro Arai, President and Chief Executive Officer, Solasia, said: “Solasia company mission is ‘Better Medicine for a Brighter Tomorrow’. We have always focused on the patients, and striven to develop innovative products to treat cancer and support cancer treatment. We continue to bring ‘quality medicines’ to the market, to benefit more patients in Asian countries. The filing of episil® will help Solasia to deliver its unwavering commitment to South Korean patients. All of team members will continue to work hard to meet the needs of patients and healthcare professionals and embrace new challenges going forward.”

About episil® episil® uses the patented FluidCrystal® technology from Camurus AB (STO:CAMX), Sweden. It is a lipid-based, preservative-free liquid that adhere to the oral mucosa. Clinically demonstrated, episil® has been shown to rapidly (within minutes) and effectively reduce oral pain for up to 8 hours. It provides physical protection to the oral sensitive and ulcerated epithelium. episil® is the only ready-to-use, pocket-sized medical device that manages and relieves oral mucositis, helping patients improve the quality of their daily lives during cancer treatment. episil® was first registered in Europe in 2009 and is now launched in the United States, Europe, Japan and other countries. episil® oral liquid is registered as Class I medical device in Europe, 510(k) medical device in the United States, and approved as Class II medical device in Japan and China.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected

spot_img

Don't Miss

Kleiner Device Labs Receives FDA Market Clearance for KG2 Surge Flow-Thru Interbody System

The system maximizes total bone graft delivery volume, better distributes graft bilaterally into the intervertebral disc space, and streamlines the implant delivery, positioning, and grafting process for TLIF and PLIF spinal fusion procedures.

Matthew Cranfill New ExtriCARE USA Director Of Clinical Services

"Matt's impressive experience and skillset easily made him our top pick," said Peter Mason, President of ExtriCARE USA.

Shannon Lantzy MedCrypt New VP of Consulting

"I met Shannon at a healthcare-related event several years ago and was immediately impressed with her passion and drive to move healthcare into a digital future," said Mike Kijewski, CEO of MedCrypt.

Mark Foster Joins Xenocor BOD

Foster is a versatile and visionary C-Suite executive who brings 20 years of general management and leadership experience from both venture-backed growth-stage organizations and world-class medical device companies

Hinge Health Acquires the Most Advanced Computer Vision Technology for Tracking Human Motion

CEO Daniel Perez explained, “We won’t stop investing in technology to deliver the most patient-centered digital clinic that improves member experience and outcomes while reducing costs. wrnch allows us to take a giant leap forward in all respects.”

Dale W Wood Congratulates the Huma Team on Raising $130 Million

Major health and technology companies across the world have committed upwards of $130 million to Huma Therapeutics, the health-tech company backed by Dale Ventures.

Rhaeos Awarded $4 Million NIH SBIR Grant

Under the NIH SBIR grant, Rhaeos will leverage their existing wireless sensor hardware to provide additional quantitative flow data to the clinician, giving insight into this currently inaccessible and highly relevant shunt performance metric.

By using this website you agree to accept Medical Device News Magazine Privacy Policy